Join the Upcoming Webinar from Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company committed to advancing neuroscience therapeutics, is excited to announce its upcoming investor webinar. This informative session will focus on its early-stage programs that aim to develop non-opioid treatments for pain, specifically targeting Kv7 and Nav1.7 ion channels.
Details of the Investor Webinar
Webinar Overview
The webinar titled 'Developing Novel Non-Opioid Treatments for Pain: An Overview of Xenon’s Nav1.7 and Kv7 Programs' will provide in-depth insights into Xenon's innovative approaches to managing pain. Participants will have the opportunity to learn from the company's top experts about the exciting developments in their research pipeline.
Date and Timing
Mark your calendars for this engaging session, which will be held on an upcoming Monday in addition to the company's existing busy schedule. The presentation will run from 11:30 AM to 12:30 PM Eastern Time, ensuring that attendees from various time zones can participate.
Interactive Format
This hour-long webinar encourages real-time engagement, allowing attendees to submit questions during the event via a chat function. For those who prefer, questions can be sent in advance, ensuring participants get the most out of the experience. This format not only informs but also fosters a dialogue between the audience and Xenon's leadership.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) stands at the forefront of neuroscience-based biopharmaceutical innovation. The company specializes in discovering, developing, and bringing to market transformative therapeutic solutions for patients facing dire health challenges. Their lead molecule, azetukalner, is undergoing Phase 3 clinical trials and represents a novel, potent treatment option for conditions such as epilepsy, major depressive disorder (MDD), and bipolar depression (BPD).
Innovative Research Pipeline
Alongside azetukalner, Xenon is championing the development of a diverse early-stage portfolio. This portfolio includes promising potassium and sodium channel modulators, with the Kv7 and Nav1.7 programs currently in Phase 1 trials focused on pain management. The potential for these treatments to provide effective pain relief without the reliance on opioids is particularly significant in today’s healthcare landscape.
Corporate Headquarters
Xenon Pharmaceuticals operates from dual locations in Vancouver, British Columbia, and Boston, Massachusetts. This bi-coastal presence enables the company to leverage diverse talent pools and innovative ecosystems in its biopharmaceutical endeavors.
Contact Information
For further inquiries about the webinar or the company's research initiatives, please contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media Contact: media@xenon-pharma.com
Investor Contact: investors@xenon-pharma.com
Frequently Asked Questions
What is the focus of the upcoming Xenon webinar?
The webinar will focus on developing non-opioid treatments for pain, discussing the Kv7 and Nav1.7 programs.
When will the webinar take place?
The webinar is scheduled to take place on an upcoming Monday from 11:30 AM to 12:30 PM Eastern Time.
How can attendees participate in the webinar?
Attendees can submit questions during the live event using the chat function or send them in advance via email.
What is Xenon's lead molecule and its significance?
Xenon's lead molecule, azetukalner, is in Phase 3 clinical trials and offers a new treatment option for epilepsy and various mood disorders.
How can I contact Xenon Pharmaceuticals for more information?
You can reach Xenon via email at investors@xenon-pharma.com or for media inquiries at media@xenon-pharma.com.
